Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes

NCT04963725 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.

NCT NCT04963725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04963725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes
Lead sponsor
Janssen Pharmaceutical K.K.
Phase
Observational
Overall status
Completed
Start date
July 18, 2021
Completion date
December 1, 2022
Enrollment
137 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis